PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors

Rebekka Duhen(Providence Portland Medical Center), Olivier Fesneau(Providence Portland Medical Center), Kimberly Samson(Providence Portland Medical Center), Alexandra K. Frye(Providence Portland Medical Center), Michael Beymer(Providence Portland Medical Center), Venkatesh Rajamanickam(Providence Portland Medical Center), David Ross(Providence Portland Medical Center), Eric Tran(Providence Portland Medical Center), Brady Bernard(Providence Portland Medical Center), Andrew D. Weinberg(Providence Portland Medical Center), Thomas Duhen(Providence Portland Medical Center)
Journal of Clinical Investigation
April 19, 2022
Cited by 70Open Access
Full Text

Abstract

CD4+ Th cells play a key role in orchestrating immune responses, but the identity of the CD4+ Th cells involved in the antitumor immune response remains to be defined. We analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4+ Th cells distinct from FOXP3+ Tregs that coexpressed programmed cell death 1 (PD-1) and ICOS. These tumor-infiltrating lymphocyte CD4+ Th cells (CD4+ Th TILs) had a tissue-resident memory phenotype, were present in MHC class II-rich areas, and proliferated in the tumor, suggesting local antigen recognition. The T cell receptor repertoire of the PD-1+ICOS+ CD4+ Th TILs was oligoclonal, with T cell clones expanded in the tumor, but present at low frequencies in the periphery. Finally, these PD-1+ICOS+ CD4+ Th TILs were shown to recognize both tumor-associated antigens and tumor-specific neoantigens. Our findings provide an approach for isolating tumor-reactive CD4+ Th TILs directly ex vivo that will help define their role in the antitumor immune response and potentially improve future adoptive T cell therapy approaches.


Related Papers

No related papers found

Powered by citation graph analysis